Neville Rodie & Shaw Inc. Sells 1,861 Shares of Eli Lilly and Company $LLY

Neville Rodie & Shaw Inc. reduced its stake in Eli Lilly and Company (NYSE:LLY) by 11.6% during the third quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 14,127 shares of the company’s stock after selling 1,861 shares during the period. Neville Rodie & Shaw Inc.’s holdings in Eli Lilly and Company were worth $10,779,000 as of its most recent SEC filing.

A number of other institutional investors have also recently made changes to their positions in LLY. Braun Bostich & Associates Inc. lifted its position in shares of Eli Lilly and Company by 2.5% in the second quarter. Braun Bostich & Associates Inc. now owns 527 shares of the company’s stock worth $411,000 after buying an additional 13 shares in the last quarter. Rise Advisors LLC increased its stake in Eli Lilly and Company by 1.8% in the 2nd quarter. Rise Advisors LLC now owns 732 shares of the company’s stock worth $571,000 after acquiring an additional 13 shares during the last quarter. Occidental Asset Management LLC raised its holdings in shares of Eli Lilly and Company by 0.7% during the 2nd quarter. Occidental Asset Management LLC now owns 1,966 shares of the company’s stock worth $1,533,000 after acquiring an additional 13 shares in the last quarter. New Insight Wealth Advisors raised its holdings in shares of Eli Lilly and Company by 3.4% during the 2nd quarter. New Insight Wealth Advisors now owns 394 shares of the company’s stock worth $307,000 after acquiring an additional 13 shares in the last quarter. Finally, Dash Acquisitions Inc. boosted its position in shares of Eli Lilly and Company by 2.8% during the 2nd quarter. Dash Acquisitions Inc. now owns 485 shares of the company’s stock valued at $387,000 after acquiring an additional 13 shares during the last quarter. Hedge funds and other institutional investors own 82.53% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities research analysts recently weighed in on LLY shares. Guggenheim restated a “buy” rating and issued a $1,163.00 price target on shares of Eli Lilly and Company in a research report on Wednesday, December 3rd. BMO Capital Markets set a $1,200.00 target price on shares of Eli Lilly and Company in a report on Thursday, December 4th. Wells Fargo & Company increased their price target on shares of Eli Lilly and Company from $1,100.00 to $1,200.00 and gave the company an “overweight” rating in a report on Wednesday, December 10th. Berenberg Bank lifted their price target on Eli Lilly and Company from $830.00 to $950.00 and gave the stock a “hold” rating in a research report on Tuesday, December 2nd. Finally, Sanford C. Bernstein upped their price objective on Eli Lilly and Company from $1,100.00 to $1,300.00 and gave the company an “outperform” rating in a research report on Monday, November 24th. Three investment analysts have rated the stock with a Strong Buy rating, seventeen have given a Buy rating and six have given a Hold rating to the company’s stock. According to data from MarketBeat.com, Eli Lilly and Company has a consensus rating of “Moderate Buy” and a consensus price target of $1,128.55.

Eli Lilly and Company Stock Up 3.4%

NYSE:LLY opened at $1,062.67 on Tuesday. The company has a market cap of $1.00 trillion, a price-to-earnings ratio of 51.99, a price-to-earnings-growth ratio of 1.14 and a beta of 0.37. Eli Lilly and Company has a twelve month low of $623.78 and a twelve month high of $1,111.99. The company has a current ratio of 1.55, a quick ratio of 1.24 and a debt-to-equity ratio of 1.71. The stock has a fifty day simple moving average of $943.82 and a 200-day simple moving average of $822.76.

Eli Lilly and Company (NYSE:LLY) last posted its quarterly earnings results on Thursday, October 30th. The company reported $7.02 EPS for the quarter, topping the consensus estimate of $6.42 by $0.60. Eli Lilly and Company had a net margin of 30.99% and a return on equity of 109.52%. The company had revenue of $17.60 billion for the quarter, compared to the consensus estimate of $16.09 billion. During the same quarter last year, the firm posted $1.18 EPS. The firm’s revenue was up 53.9% compared to the same quarter last year. Eli Lilly and Company has set its FY 2025 guidance at 23.000-23.700 EPS. Analysts anticipate that Eli Lilly and Company will post 23.48 EPS for the current year.

Eli Lilly and Company Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, March 10th. Stockholders of record on Friday, February 13th will be paid a dividend of $1.73 per share. This is a boost from Eli Lilly and Company’s previous quarterly dividend of $1.50. This represents a $6.92 annualized dividend and a dividend yield of 0.7%. The ex-dividend date of this dividend is Friday, February 13th. Eli Lilly and Company’s payout ratio is presently 29.35%.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.